The Role of Cell Death In Cancer and Therapeutic Targets

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.

Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46.

Dandoti S. Mechanisms adopted by cancer cells to escape apoptosis–A review. Biocell. 2021;45(4):863.

Morana O, Wood W, Gregory CD. The apoptosis paradox in cancer. Int J Mol Sci. 2022;23(3):1328.

Peng F, Liao M, Qin R, Zhu S, Peng C, Fu L, et al. Regulated cell death (RCD) in cancer: key pathways and targeted therapies. Signal Transduct Target Ther. 2022;7(1):286.

Tong X, Tang R, Xiao M, Xu J, Wang W, Zhang B, et al. Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research. J Hematol Oncol. 2022;15(1):174.

Wang S, Guo S, Guo J, Du Q, Wu C, Wu Y, Zhang Y. Cell death pathways: molecular mechanisms and therapeutic targets for cancer. MedComm. 2024;5(9):e693.

Yuan J, Ofengeim D. A guide to cell death pathways. Nat Rev Mol Cell Biol. 2024;25(5):379–95.

Santagostino SF, Assenmacher CA, Tarrant JC, Adedeji AO, Radaelli E. Mechanisms of regulated cell death: current perspectives. Vet Pathol. 2021;58(4):596-623.

Mustafa M, Ahmad R, Tantry IQ, Ahmad W, Siddiqui S, Alam M, et al. Apoptosis: a comprehensive overview of signaling pathways, morphological changes, and physiological significance and therapeutic implications. Cells. 2024;13(22):1838.

Yasmin T, Kabir Y. Apoptosis in cancer. In: Rezaei N, editor. Cancerous Cells. Handbook of Cancer and Immunology. Vol 2. Cham: Springer; 2025.

Chen Z, Wang W, Abdul Razak SR, et al. Ferroptosis as a potential target for cancer therapy. Cell Death Dis. 2023;14:460.

Mao C, Wang M, Zhuang L, Gan B. Metabolic cell death in cancer: ferroptosis, cuproptosis, disulfidptosis, and beyond. Protein Cell. 2024;15(9):642–60.

Debnath J, Gammoh N, Ryan KM. Autophagy and autophagy-related pathways in cancer. Nat Rev Mol Cell Biol. 2023;24(8):560–75.

Liu S, Yao S, Yang H, Liu S, Wang Y. Autophagy: regulator of cell death. Cell Death Dis. 2023;14(10):648.

Niu X, You Q, Hou K, Tian Y, Wei P, Zhu Y, et al. Autophagy in cancer development, immune evasion, and drug resistance. Drug Resist Updat. 2025;78:101170.

Yan J, Wan P, Choksi S, Liu ZG. Necroptosis and tumor progression. Trends Cancer. 2022;8(1):21–7.

Zhang Z, Zhang F, Xie W, Niu Y, Wang H, Li G, et al. Induced necroptosis and its role in cancer immunotherapy. Int J Mol Sci. 2024;25(19):10760.

Jia Y, Wang X, Deng Y, Li S, Xu X, Qin Y, Peng L. Pyroptosis provides new strategies for the treatment of cancer. J Cancer. 2023;14(1):140.

Liu SW, Song WJ, Ma GK, Wang H, Yang L. Pyroptosis and its role in cancer. World J Clin Cases. 2023;11(11):2386.

Newton K, Strasser A, Kayagaki N, Dixit VM. Cell death. Cell. 2024;187(2):235–56.

Di Cristofano F, George A, Tajiknia V, Ghandali M, Wu L, Zhang Y, et al. Therapeutic targeting of TRAIL death receptors. Biochem Soc Trans. 2023;51(1):57–70.

Pfeffer CM, Singh ATK. Apoptosis: A target for anticancer therapy. Int J Mol Sci. 2018;19(2):448.

Shenoy B, Mandani M, Chintamaneni M, Manohar SM. Combination of the first-in-class imipridone ONC201 and standard anticancer therapies as a rational approach for therapeutic benefit. Curr Issues Mol Biol. 2025;47(9):775.

LoRusso P, Ratain MJ, Doi T, Rasco DW, de Jonge MJ, Moreno V, et al. Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study. Invest New Drugs. 2022;40(4):762–72.

Sp N, Kang DY, Jo ES, Rugamba A, Kim WS, Park YM, et al. Tannic acid promotes TRAIL-induced extrinsic apoptosis by regulating mitochondrial ROS in human embryonic carcinoma cells. Cells. 2020;9(2):282.

Chiu CF, Lin YQ, Park JM, Chen YC, Hung SW, Chiu CC, Chang CF. The novel camptothecin derivative, CPT211, induces cell cycle arrest and apoptosis in models of human breast cancer. Biomed Pharmacother. 2020;128:110309.

You Y, Guo Z, Wolter T, Hu Q. Intracellular metal ion-based chemistry for programmed cell death. Chem Soc Rev. 2025; 54, 1552-1582.

Yamaguchi R, Lartigue L, Perkins G. Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy. Pharmacol Ther. 2019;195:13–20.

Croce CM, Vaux D, Strasser A, Opferman JT, Czabotar PE, Fesik SW. The BCL-2 protein family: from discovery to drug development. Cell Death Differ. 2025;1–13.

Tang Y, Li S, Rao P, Yu W, Jiang X, Liu J. Therapeutic drug monitoring: a new hope for individualised treatment with venetoclax. Curr Drug Targets. 2025.

Song S, Chen Q, Li Y, Lei G, Scott A, Huo L, et al. Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma. Gut. 2021;70(12):2238–48.

Desai P, Lonial S, Cashen A, Kamdar M, Flinn I, O’Brien S, et al. A phase 1 first-in-human study of the MCL-1 inhibitor AZD5991 in patients with relapsed/refractory hematologic malignancies. Clin Cancer Res. 2024;30(21):4844–55.

Chen M, Shi Z, Sun Y, Ning H, Gu X, Zhang L. Prospects for anti-tumor mechanism and potential clinical application based on glutathione peroxidase 4 mediated ferroptosis. Int J Mol Sci. 2023;24(2):1607.

Rochette L, Dogon G, Rigal E, Zeller M, Cottin Y, Vergely C. Lipid peroxidation and iron metabolism: two corner stones in the homeostasis control of ferroptosis. Int J Mol Sci. 2024;24(1):449.

Chen H, Wang C, Liu Z, He X, Tang W, He L, et al. Ferroptosis and its multifaceted role in cancer: mechanisms and therapeutic approach. Antioxidants. 2022;11(8):1504.

Jiang M, Wu W, Xiong Z, Yu X, Ye Z, Wu Z. Targeting autophagy drug discovery: targets, indications and development trends. Eur J Med Chem. 2024;267:116117.

Mohsen S, Sobash PT, Algwaiz GF, Nasef N, Al-Zeidaneen SA, Karim NA. Autophagy agents in clinical trials for cancer therapy: a brief review. Curr Oncol. 2022;29(3):1695–708.

Chen JL, Wu X, Yin D, Jia XH, Chen X, Gu ZY, Zhu XM. Autophagy inhibitors for cancer therapy: small molecules and nanomedicines. Pharmacol Ther. 2023;249:108485.

Seo J, Nam YW, Kim S, Oh DB, Song J. Necroptosis molecular mechanisms: recent findings regarding novel necroptosis regulators. Exp Mol Med. 2021;53(6):1007–17.

Zhou Y, Cai Z, Zhai Y, Yu J, He Q, He Y, et al. Necroptosis inhibitors: mechanisms of action and therapeutic potential. Apoptosis. 2024;29(1):22–44.

Huang C, Li J, Wu R, Li Y, Zhang C. Targeting pyroptosis for cancer immunotherapy: mechanistic insights and clinical perspectives. Mol Cancer. 2025;24(1):131.

Dhani S, Zhao Y, Zhivotovsky B. A long way to go: caspase inhibitors in clinical use. Cell Death Dis. 2021;12(10):949.

Dai Z, Liu WC, Chen XY, Wang X, Li JL, Zhang X. Gasdermin D-mediated pyroptosis: mechanisms, diseases, and inhibitors. Front Immunol. 2023;14:1178662.

Beltrán-Visiedo M, Soler-Agesta R, Sarosiek KA, Green DR, Galluzzi L. Regulation of inflammatory processes by caspases. Nat Rev Mol Cell Biol. 2025;1–18.

An X, Yu W, Liu J, Tang D, Yang L, Chen X. Oxidative cell death in cancer: mechanisms and therapeutic opportunities. Cell Death Dis. 2024;15(8):556.

Wang W, Li T, Wu K. Cell death in tumor microenvironment: an insight for exploiting novel therapeutic approaches. Cell Death Discov. 2025;11(1):93.

D’Amico M, De Amicis F. Challenges of regulated cell death: implications for therapy resistance in cancer. Cells. 2024;13(13):1083.

Shi X, Wang X, Yao W, et al. Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives. Signal Transduct Target Ther. 2024;9:192.

Prajapati VK. Innovation in Cell Death Research. Vol 217. Cambridge, MA: Academic Press; 2025.